🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
Joined March 2019
- Tweets127K
- Following139
- Followers42.8K
- Likes139K
Pinned Tweet
NEW | OncoAlert HORIZONS🌅: Breast Cancer
PI3K pathway in HR+/HER2– breast cancer: testing, treatment and the next wave 🧬
@BarbaraPistill2 (@GustaveRoussy ) and @CristinaSaura3 (@VHIO ) cover:
🔹 Unequal access to PI3K pathway drugs across Europe
🔹 When to test for PIK3CA: up front or after CDK4/6 inhibitors?
🔹 ESR1 + PIK3CA co-mutation: SERD or PI3K inhibitor first?
🔹 Next-generation inhibitors with less hyperglycemia
🔹 Oral vs. weekly IV treatment and patient preference
HORIZONS FACULTY: @LoiSher, @JavierCortesMD, @BarbaraPistill2, @BianchiniGP, @ElisaAgostinett, Sybille Loibl, Rupert Barsch, François-Clément Bidard, Cristina Saura.
Pinging our Breast Cancer faculty
@matteolambe, @aftimosp, @E_de_Azambuja, @DrSGraff, @ErikaHamilton9, @double_whammied, @maryam_lustberg, @raalbany, @hoperugo, @stolaney1, @LoiSher, @SirohiBhawna, @jamecancerdoc, @JavierCortesMD, @JaniceTNBCmets, @Prof_Nadia_H, @nataliagandur, @FernandoOnco, @to_be_elizabeth, @Lucarecco, @GaiaGriguolo, @JankovicK, @MarioBalsaMD, @Dr_Oncologista.
Made possible thanks to an unrestricted educational grant by Roche
Is the next generation of KRAS G12C inhibitors changing the treatment landscape in advanced NSCLC 🫁 ?
nejm.org/doi/full/10.1056/NE…
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
@FSkoulidis, @ShirishGadgeel, @DrSanjayPopat, @MDuruisseaux, @WadeIams, @JulienMazieres, @Decoster_Lore, @EnriquetaFelip, @mollylisc, @AkamatsuHiroaki, @k_cupp_, @MartinReck2, @bensolomon1
A new phase 3 trial puts divarasib head-to-head against existing 🧬 KRAS G12C inhibitors, with encouraging results.
➡️ In previously treated KRAS G12C-mutated advanced NSCLC, divarasib significantly improved median progression-free survival (9.8 vs 5.7 months; HR 0.58) and overall survival (17.7 vs 12.0 months; HR 0.56) compared with sotorasib or adagrasib.
➡️ Response rates were also higher (58.4% vs 32.3%), with fewer grade 3–4 treatment-related adverse events (24.6% vs 34.5%). #LungCancer #NSCLC
Pinging Lung Cancer Faculty
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
OncoAlert retweeted
Negative phase III KEYNOTE-867 @JCO_ASCO. Pts with stage I-II NSCLC treated with SBRT with pembro vs placebo (n=448). No difference in EFS (31.2 vs 28.3m, HR 0.92). Poor partner, wrong setting, or both? Adjuvant IO approaches in general disappointing.
ascopubs.org/doi/10.1200/JCO…
OncoAlert retweeted
CARBOPLATIN IN EARLY TNBC | More Than Just pCR?
A 2026 pooled analysis of 3 randomized trials (n = 1,084) offers important insights:
🔹 pCR: Improved with carboplatin (OR 1.89).
🔹 EFS: Significant benefit (HR 0.71) — 29% lower hazard of an EFS event.
🔹 OS: No statistically significant improvement (HR 0.93).
🔹 gBRCA1/2: Encouraging EFS signal (HR 0.50; P = .05).
🔹 Biomarkers: None validated to predict additional carboplatin benefit.
Take-home: Carboplatin improves pCR and EFS, but an OS benefit remains unproven. These findings come from the pre-immunotherapy era.
📖 Felsheim et al. JCO Oncology Advances, 2026.
@OncoAlert @OncoDaily @larvol
#TNBC #BreastCancer #Carboplatin #Oncology #MedOnc
OncoAlert retweeted
Would you like a glimpse of the future? Where solid tumor oncology may be heading?
Look no further.
Agenus may have had some ups and downs in the past (BATMAN -> ROBBIN), but Bot Bal looks like it has the capacity to absolutely change how we manage MSS solid tumors.
UNICORN, now in Nature Medicine. Phase 2, non-randomized, window-of-opportunity. Resectable rT3-4 colon cancer. One dose of botensilimab, two doses of balstilimab, surgery around day 30-40.
Highlights:
MPR 36% (5/14) in MSS disease, pCR 29%. Omg. (compare to FOLFOX in FOxTROT: 8%)
Bot alone in MSS: 0%. The PD-1 matters.
dMMR Bot Bal: MPR 100%, pCR 93%
😍12-month EFS 100% in both Bot Bal cohorts
Yes there is tox. irAEs in 54%, mostly flu-like symptoms, and only one grade 3 (hyperthyroidism). No grade 3 diarrhea.
Every MSS responder cleared ctDNA before surgery, that’s a helpful tool for predicting response in a disease that may fibrose and stay visible on imaging.
The holy grail is almost here: melting the majority of rectal cancers away. In MSI-H we have AZUR-1. In MSS, perhaps we have this in the future.
nature.com/articles/s41591-0…
@OncoAlert @TheGutOncLab @Onco_Nexus
OncoAlert retweeted
🔥Global cancer treatment costs for 31 cancer types: systematic review & modeling study
🆙 @TheLancetOncol
🎯Total 10-y costs for 2022 diagnoses: $771.5 billion
🥇Breast Cancer $96.07 billion
🥈Leukaemia $86.11 billion
🥉Lung cancer $84.4 billion
🎯Mean cost per patient $38,650 globally ($3,380 E. Africa vs $93,600 N. America)
🎯Stage IV costs rising over time
🎙Dr. Zachary Ward
#LCSM @OncoAlert @Larvol @IASLC
thelancet.com/journals/lanon…
OncoAlert retweeted
🔥ADRIATIC: Patterns of progression with durvalumab vs placebo after cCRT in LS-SCLC
🆙 @JTOonline @IASLC
🎯Extrathoracic progression 20.1 vs 30.1%; brain 6.8 vs 12.4% (durvalumab vs placebo)
🎯Time to extrathoracic progression/death (durvalumab vs placebo): HR 0.68; brain HR 0.64; intrathoracic HR 0.81
🎙Dr. Suresh Senan
#LCSM @OncoAlert @Larvol
🔥#LBA5 ADRIATIC: Durva after CRT in LS-SCLC
🎙️@DavidRSpigel
🎯PFS HR 0.76 [95%CI 0.61–0.95]
🎯OS HR 0.73 [95%CI 0.57–0.93]
🎯Definite standard of care with double PFS&OS☀️
✅Primary OS&PFS
✅NCT03703297
#ASCO24 #LCSM @OncoAlert @ASCO
meetings.asco.org/abstracts-…
OncoAlert retweeted
ESMO 2026 | Gynaecological Cancers
7 trials. 3 cancers. One infographic.
🟢 TroFuse-005, KEYNOTE-C93 & BEATcc: Survival/PFS gains.
🟠 NRG-GY020 & DUO-E: Important statistical cautions.
🟣 BEHOLD-1 & FONTANA: Promising ADC activity, awaiting survival data.
Take-home: Proven benefit ≠ early promise.
@myESMO @OncoAlert @OncoDaily @larvol
#ESMO26 #GynOnc #Oncology
OncoAlert retweeted
🚨 Is immunotherapy finally breaking the pMMR colon cancer barrier?
The phase II UNICORN trial, published in Nature Medicine, reports striking pathological responses with neoadjuvant botensilimab + balstilimab.
🔬 56 patients | Resectable T3–4 colon cancer
Major pathological response (≤10% viable tumor):
🔹 pMMR colon cancer
* Botensilimab alone: 0%
* BOT + BAL: 36%
* pCR with combination: 29%
🔹 dMMR colon cancer
* Botensilimab alone: 36%
* BOT + BAL: 100%
* pCR with combination: 93% (13/14)
🔥 The most intriguing finding?
Even traditionally immunotherapy-resistant pMMR tumors demonstrated meaningful pathological regression with Fc-enhanced CTLA-4 blockade plus PD-1 inhibition.
📊 12-month EFS: 100% in both combination cohorts, although follow-up remains immature.
⚠️ Important limitations: Small, nonrandomized cohorts (n=14 each), pathological response as the primary endpoint, and no definitive survival comparison.
💡 My take: The 93% pCR in dMMR is remarkable, but the 36% major pathological response in pMMR may be the more biologically provocative signal.
Could next-generation CTLA-4 antibodies finally expand immunotherapy beyond dMMR colon cancer?
@oncoalert @NatureMedicine
#ColonCancer #Immunotherapy #UNICORNTrial
Full paper link in comment below ⬇️
OncoAlert retweeted
🚨Join us as we return with the wonderful @JenSeligmann to complete our tour of Peri-operative therapy in Colon Cancer💥
🎙️Jenny walks us through this landscape with ease 🙌🏽
🎙️Can MMRp patient a get a benefit from IO??
Enjoy💃
@OncoAlert @myESMO @bowelcancer @bowelcanceruk
🤖 Made with AI
OncoAlert retweeted
The Netherlands 🇳🇱 @LAUrology_NL @MichvdHeijden World Cup #UromigosLive video is going to be difficult to beat. Vote (❤️=vote) for your best video to win the cup. Italy 🇮🇹 tomorrow then Japan 🇯🇵 and China 🇨🇳 !! Previous winners include Los Angeles @montypal @TDorffOnc @neerajaiims @PGrivasMDPhD and 🇺🇸 @DrChoueiri @OncoAlert - can a team outside of USA 🇺🇸 win? Tune into the Live bladder session (2pm EST 13th Nov) - ‘What’s the standard of care in muscle invasive bladder cancer?’ @DrRosenbergMSK @shilpaonc @@MattGalsky @JoshMeeks
The Uromigos World Cup is here! Countries are competing for the ultimate prize: the 🏆!
First up, Team Netherlands 🇳🇱
#UromigosLive
📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow**
📅 November 11–13, 2026
📍 New York, NY 🇺🇸
💻 Hybrid Meeting — In Person + Online
🎟️ FREE REGISTRATION with code: ONCOALERT
👉 buff.ly/b5A7hsf
For more than four decades, CFS® has brought together oncology professionals from around the world to explore the latest advances in cancer care.
This 3-day meeting will feature internationally renowned experts discussing practice-changing developments across **solid tumors and hematologic malignancies**, including:
🔹 Targeted therapies & immunotherapies\
🔹 Novel biomarkers and biomarker-driven treatment approaches\
🔹 Results from pivotal clinical trials\
🔹 Personalized treatment strategies based on evolving evidence\
🔹 Management of adverse events associated with novel therapies\
🔹 Emerging combination treatment strategies
🎓 Program Co-Chairs:
• Benjamin Levy, MD\
• John Mascarenhas, MD\
• Tiffany Traina, MD, FASCO
Don't miss this opportunity to connect with leaders in oncology, stay up to date on the latest evidence, and explore what’s next in cancer care.
🔗 **Register now:** buff.ly/b5A7hsf
@KCArbourMD @mishabeltran @KellyLBolton @HosseinBorghaei @AjaiChari @End\_myeloma @DrPinkalDesai @FordePatrick @MattGalsky @YJanjigianMD @DrHKantarjian @montypal @szusmani @HelenaYu923 @gotoPER
OncoAlert retweeted
Similar response rates. Different trial outcomes. 🎙️
In Episode 521, Rob Jones joins the Uromigos to unpack differing chemotherapy–immunotherapy trial results in muscle invasive bladder cancer, what pathologic complete response really tells us, and how patient selection may shape outcomes.
Swipe for the highlights, then tune in for the full discussion: bit.ly/4eZI6ts
#Uromigos #ESMO26
OncoAlert retweeted
The Uromigos World Cup is here! Countries are competing for the ultimate prize: the 🏆!
First up, Team Netherlands 🇳🇱
#UromigosLive
OncoAlert retweeted
New & available #OpenAccess 🔓 In patients with acute myeloid leukemia, eltrombopag did not improve survival but was feasible and safe when initiated after chemotherapy washout and decreased the need for platelet transfusions.
🔗: acsjournals.onlinelibrary.wi…
@OncoAlert #leusm
OncoAlert retweeted
A passionate advocate + our newest advisory council Chair! 🧡👏
Congratulations @jferrell512 on this new role! A #kidneycancer survivor and longtime KCA supporter, John co-founded @ferrfoundation, which has generously funded our Patient Assistance Fund. Excited for all ahead!
OncoAlert retweeted
Great Results from DeLLphi-305 🫁 however with CRS in nearly half of patients, this means readiness is the real challenge now. Monitoring pathways, step-up dosing logistics and training community teams will decide how quickly this reaches patients outside academic centres. #LungCancer
DeLLphi-305🚨 A 0.42 hazard ratio for death in extensive-stage small-cell lung cancer. In a disease where we’ve celebrated gains of two to three months, this is a different level. 🫁
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
nejm.org/doi/full/10.1056/NE…
@MP_3855, @ADesaiMD
📊 In the open-label phase 3 DeLLphi-305 trial, 563 patients with extensive-stage SCLC without progression after first-line chemoimmunotherapy were randomized to tarlatamab plus durvalumab or durvalumab alone as maintenance. The median overall survival was 21.1 versus 12.7 months (HR 0.42), and the median PFS 7.4 versus 1.9 months (HR 0.34). Grade ≥3 adverse events occurred in 46.8% versus 40.6%; cytokine release syndrome, mostly grade 1–2, affected nearly half of tarlatamab-treated patients. #LungCancer
Pinging our faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
OncoAlert retweeted
Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial
#cancer #oncology #MedX @OncoAlert
nature.com/articles/s41591-0…
OncoAlert retweeted
🧬 UNICORN | Phase II (N=56), resectable colon cancer, neoadj BOT +/- BAL
🎯 MPR (4 cohorts; n=14 each):
🔬 pMMR + BOT: 0%
🔬 pMMR + BOT/BAL: 36%
🔬 dMMR + BOT: 36%
🔬 dMMR + BOT/BAL: 100%
🔗 doi.org/10.1038/s41591-026-0…
@OncoAlert
OncoAlert retweeted
Many oncology clinics lack gender-affirming practices. @CancerCareMASCC offer guidance on cancer care for transgender & gender-diverse people:
✅ Avoid gender assumptions
✅ Use affirmed names/pronouns
✅ Provide gender-neutral facilities
acsjournals.onlinelibrary.wi…
@OncoAlert
